Analysis of the Varieties and Indications of Anti-tumor Drugs Included in the Medical Insurance in Recent 5 Years
OBJECTIVE To analyze the changes in the types of anti-tumor drugs negotiated during the five-year National Medical Insurance catalog agreement period from 2019 to 2023 and the changes in the scope of payment dis-eases limited by medical insurance,the indications of monoclonal antibodies and protein kinase inhibitors were ana-lyzed.MTEHODS In the form of a table,the number of anti-tumor drugs negotiated during the fifth edition of the National Medical Insurance catalogue agreement,the year of inclusion and the scope of payment limited by medical insurance were listed.RESULTS The total number of anti-tumor drugs negotiated during the agreement period in the fifth edition of the National Medical insurance catalog showed an increasing trend year by year,and the top 3 types of anti-tumor drugs were protein kinase inhibitors,monoclonal antibodies and other anti-tumor drugs.The pay-ment diseases limited by the medical insurance cover tumors of various systems,such as respiratory system,digestive system,blood system,urinary system,mammary gland,etc.,of which the respiratory system accounts for the highest proportion.Some varieties entered the national negotiation drug list for five consecutive years.CONCLUSION Tra-ditional anti-tumor drugs have been gradually replaced by new anti-tumor drugs in recent years due to their adverse reactions.However,due to the high price of new anti-tumor drugs and the long-term use of patients,national interven-tion is needed to reduce the price as much as possible to meet the drug needs and accessibility of cancer patients,so as to reduce the economic burden and improve the quality of life.
National medical insurance directoryNegotiate drugs during the agreement periodAntitumor agentsProtein kinase inhibitorsMonoclonal antibody
万方数据
维普
